Results 121 to 130 of about 23,635 (276)

Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor in primary care: Case report

Turkish Journal of Family Practice
Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies suggest dipeptidyl peptidase-4 inhibitors used in the treatment of type-2 diabetes as possible predisposing agents of bullous pemphigoid.
Kübra Kurt
doaj   +1 more source

Retrospective analysis of cutaneous immune‐related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA‐B*51:01 allele

Cancer, Volume 132, Issue 3, 1 February 2026.
ABSTRACT Background While immune checkpoint inhibitors (ICIs) have shown significant efficacy, a common side effect is cutaneous immune‐related adverse events (irAEs). This study focuses on exploring the association between specific human leukocyte antigen (HLA) alleles and the development of cutaneous irAEs in melanoma patients undergoing ICI ...
Mckenzie DiLeo, Samantha Oglesby, Cheuk Hong Leung, Kristen E. Pauken, Sahira Farooq, Lauren E. Haydu, Shelby L. Kubicki, Rebeca Martinez, Macartney Welborn, Sana Zahiruddin, Jun Zou, Kai Cao, Anisha B. Patel   +12 more
wiley   +1 more source

Navigating the Complexities of Pemphigus Vulgaris: A Comprehensive Iranian Study

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
We conducted a cross‐sectional analysis of 63 patients diagnosed with pemphigus vulgaris, confirmed by biopsy. Information was collected via telephone interviews. The research aimed to assess the demographic characteristics, initial symptoms, diagnosis delays, and treatment outcomes of the participants.
Delaram Moosavi, Seyed Mohammad Mahdi Khadem, Afsaneh Sadeghzadeh Bazargan, Kambiz Kamyab Hesari, Mehrnaz Azh, Hamed Zarei Sharif, Nasrin Shayanfar, Azadeh Goodarzi   +7 more
wiley   +1 more source

Comment on “Association of bullous pemphigoid with malignancy: A systematic review and meta-analysis” [PDF]

, 2018
Roberto Maglie, Emiliano Antiga, Marzia Caproni   +2 more
openalex   +1 more source

Sita‐ and saxagliptin use and autoantibodies to autoimmune bullous diseases: A cross‐sectional study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Sören Dräger, Claudia Kauderer, Svenja Meyhöfer, Leonie Dräger, Jens U. Marquardt, Ralf J. Ludwig, Stephan Arndt, Katharina Boch, Katja Bieber   +8 more
wiley   +1 more source

Chronic Rhinosinusitis and Autoimmune Diseases: A Comprehensive Large Population‐Based Analysis

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
ABSTRACT Objectives To evaluate associations between a wide variety of autoimmune diseases and chronic rhinosinusitis without nasal polyposis (CRSsNP), CRS with nasal polyposis (CRSwNP), and the need for endoscopic sinus surgery. Methods This is a multicenter retrospective study from January 1, 2010 to July 31, 2025 utilizing data from 106 healthcare ...
Robert E. Africa, Brian J. McKinnon, Charles A. Hughes, Scott A. Hardison   +3 more
wiley   +1 more source

Differential risks of venous thromboembolic events in pemphigus and pemphigoid diseases

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Maren E. Buenning, Sri Harini Purusothaman, Svea Symannek, Philip Curman, Khalaf Kridin, Enno Schmidt, Katja Bieber, Ralf J. Ludwig   +7 more
wiley   +1 more source

Pharmacogenomics of Thiopurine Drugs: A Bench‐To‐Bedside Success Story in Thailand

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT Thiopurine drugs are the cornerstone treatment for many diseases such as acute lymphoblastic leukemia (ALL), organ rejection, inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other autoimmune diseases.
Mohitosh Biswas, Shobana John, Murshadul Alam Murad, Chonlaphat Sukasem   +3 more
wiley   +1 more source

Risk of persistent hypogammaglobulinaemia in children with autoimmune bullous dermatoses treated with rituximab

Journal of the European Academy of Dermatology and Venereology, EarlyView.
S. Benkimoun, A. Welfringer‐Morin, V. Barlogis, R. Gravier Dumonceau, E. Bourrat, C. Chiaverini, C. Léauté‐Labrèze, P. Joly, B. Tedbirt, A.‐C. Bursztejn, G. Font, C. Bodemer, M.‐A. Richard, S. Mallet, Groupe Bulles of the French Society of Dermatology; Clinical Research Group of the French Society of Pediatric Dermatology   +14 more
wiley   +1 more source

156 COVID-19 vaccine is a risk factor accelerating time to bullous pemphigoid onset [PDF]

, 2023
A. Pira, F. Mariotti, F. Moro, A. Panebianco, S. Pallotta, B. Didona, Giovanni Di Zenzo   +6 more
openalex   +1 more source